141 related articles for article (PubMed ID: 34115004)
1. Assessment of the viability and treatment response of bone metastases in patients with metastatic castration-resistant prostate cancer using choline PET/CT.
Kitajima K; Yamamoto S; Kawanaka Y; Komoto H; Shimatani K; Hanasaki T; Taguchi M; Nagasawa S; Yamada Y; Kanematsu A; Yamakado K
Medicine (Baltimore); 2021 Jun; 100(23):e26206. PubMed ID: 34115004
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases.
Donners R; Tunariu N; Tovey H; Hall E; Chua S; Cook G; Du Y; Blackledge MD; Parker CC; Koh DM
Eur Radiol; 2024 Feb; 34(2):1146-1154. PubMed ID: 37615760
[TBL] [Abstract][Full Text] [Related]
4. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
Jimbo M; Andrews JR; Ahmed ME; Dundar A; Karnes RJ; Bryce AH; Kendi AT; Kwon ED; Lowe VJ; Bold MS
Prostate; 2022 Jan; 82(1):41-48. PubMed ID: 34633087
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of [
Schwarzenböck SM; Eiber M; Kundt G; Retz M; Sakretz M; Kurth J; Treiber U; Nawroth R; Rummeny EJ; Gschwend JE; Schwaiger M; Thalgott M; Krause BJ
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2105-2113. PubMed ID: 27317482
[TBL] [Abstract][Full Text] [Related]
7. Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer.
Nozaki K; Kawai T; Fujimura T; Matsui H; Teshima T; Oshina T; Takahashi A; Sato Y; Yamada D; Azuma T; Hotta M; Nakajima K; Nakayama H; Minamimoto R; Kume H
Int Urol Nephrol; 2019 Oct; 51(10):1763-1769. PubMed ID: 31325132
[TBL] [Abstract][Full Text] [Related]
8. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
Alamiri J; Britton CJ; Ahmed ME; Andrews JR; Higa JL; Dundar A; Karnes RJ; Kwon E; Lowe VJ; Kendi AT; Bold MS; Pagliaro LC
Prostate; 2022 Dec; 82(16):1483-1490. PubMed ID: 36089822
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of
Kitajima K; Fukushima K; Yamamoto S; Kato T; Odawara S; Takaki H; Fujiwara M; Yamakado K; Nakanishi Y; Kanematsu A; Nojima M; Hirota S
Nagoya J Med Sci; 2017 Aug; 79(3):387-399. PubMed ID: 28878443
[TBL] [Abstract][Full Text] [Related]
10. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Treatment Response in Prostate Cancer and Renal Cell Carcinoma Patients Using 11C-choline PET/CT Findings.
Kitajima K; Yamamoto S; Nakanishi Y; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Fujiwara M; Kaida H; Tsurusaki M; Kanda T; Tamaki Y; Yamakado K
Acta Med Okayama; 2019 Aug; 73(4):341-347. PubMed ID: 31439957
[TBL] [Abstract][Full Text] [Related]
12. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
Özülker T; Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223.
Scalzi P; Baiocco C; Genovese S; Trevisan A; Sirotova Z; Poti C
Urologia; 2017 Feb; 84(1):61-64. PubMed ID: 27911459
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Performance of 11C-choline PET/CT and FDG PET/CT in Prostate Cancer.
Kitajima K; Yamamoto S; Odawara S; Kobayashi K; Fujiwara M; Kamikonya N; Fukushima K; Nakanishi Y; Hashimoto T; Yamada Y; Suzuki T; Kanematsu A; Nojima M; Yamakado K
Acta Med Okayama; 2018 Jun; 72(3):289-296. PubMed ID: 29926007
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of
Kimura K; Kitajima K; Kawanaka Y; Yokoyama H; Komoto H; Fujiwara M; Furukawa Y; Kanematsu A; Yamamoto S; Miyake H; Yamakado K
Int J Urol; 2022 Sep; 29(9):1072-1078. PubMed ID: 35875967
[TBL] [Abstract][Full Text] [Related]
18. Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT.
Kitajima K; Yamamoto S; Fujiwara M; Kawanaka Y; Yamada Y; Nagasawa S; Shimatani K; Hanasaki T; Taguchi M; Kanematsu A; Yamakado K
Case Rep Oncol; 2021; 14(1):520-524. PubMed ID: 33976628
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E
Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648
[TBL] [Abstract][Full Text] [Related]
20. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]